Search clinical trials for: Placebo (NNC0113-2023)

Total 53762 results

Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0113-6856 in Healthy Males

Type 2 Diabetes | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

Type 2 Diabetes | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Recruiting

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Healthy Participants

Germany
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Sarang K. Yoon, DO, MOH
Novavax; Westat

Recruiting

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection (BEEHIVE)

COVID-19 | SARS CoV 2 Infection | Vaccine-Preventable Diseases | Upper Respiratory Tract Infection | Upper Respiratory Disease

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Spain, Hungary, Serbia, Bulgaria, Poland, Russian Federation, Latvia
Novo Nordisk A/S

Completed

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Russian Federation, Germany
Novo Nordisk A/S

Terminated

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

Serbia, Hungary, Poland, United States
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Inflammation | Crohn's Disease

United States, Spain, Bulgaria, Czech Republic, Poland, Slovakia
Novo Nordisk A/S

Recruiting

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Healthy Volunteers (Diabetes Mellitus, Type 2)

Denmark, Germany
Promentis Pharmaceuticals, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

Healthy Volunteers

United States
Promentis Pharmaceuticals, Inc.

Completed

A Study in Patients With Trichotillomania (TTM)

Trichotillomania

United States
Novo Nordisk A/S

Completed

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Inflammation | Healthy | Rheumatoid Arthritis

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Denmark, Poland, Spain, Czechia
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

Non-alcoholic Steatohepatitis

Japan
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Overweight or Obesity | Metabolism and Nutrition Disorders

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
Promentis Pharmaceuticals, Inc.
Celerion

Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

Healthy

United States
NVP Healthcare

Recruiting

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Cardiovascular Diseases

Korea, Republic of
Novo Nordisk A/S

Completed

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Janssen Research & Development, LLC

Completed

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Radboud University Medical Center
GlaxoSmithKline

Completed

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Influenza | Herpes Zoster

Netherlands
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Diabetes Mellitus, Type 2

Japan
Janssen Research & Development, LLC

Completed

Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Ukraine
McMaster University
Canadian Institutes of Health Research (CIHR)

Recruiting

Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1 (RIPPLE-C)

Diabetes Mellitus | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Osteoarthritis | Dementia | Congestive Heart Failure | Depression, Anxiety

Canada
National Institute on Drug Abuse (NIDA)
Technical Resources International, Inc.; Promentis Pharmaceuticals, Inc.; Altasciences...

Not yet recruiting

SXC-2023 Cocaine Interaction Study

Cocaine Use Disorder

United States
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
Novo Nordisk A/S

Completed

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Promentis Pharmaceuticals, Inc.
Baylor College of Medicine; Celerion

Completed

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

Impulse Control Disorders

United States
Novo Nordisk A/S

Completed

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Biotie Therapies Corp.

Completed

BTT-1023 in Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria
CuraSen Therapeutics, Inc.

Withdrawn

A Study of CST-2032 in Subjects With Cognitive Impairment

Mild Cognitive Impairment (MCI) | Parkinson Disease (PD)
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Eisai Inc.

Recruiting

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)

Epilepsies, Myoclonic

United States, Canada

3

Subscribe